About Us
Our Company
Our People
Our Science
Our Science
Precise Antibody Engineering
Cytokine-Fusion Antibody
Novel T cell Targets
Pipeline
Pipeline
MMB101
MMB102
MFA011
Partnering
News
About Us
Our Company
Our People
Our Science
Our Science
Precise Antibody Engineering
Cytokine-Fusion Antibody
Novel T cell Targets
Pipeline
Pipeline
MMB101
MMB102
MFA011
Partnering
News
About us
Our Company
Our People
Contact
Home
Our Science
Cytokine-Fusion Antibody
Novel T cell Targets
Precise Antibody Engineering
Partnering with Us
Pipeline
MFA011
MMB101
MMB102
News
2020-05-27
MediMabBio establishes UK Subsidiary, MediMab Biotherapeutics
2019-02-19
MediMabBio Secures $3 Million Investment to Advance “New-Generation Cancer Treatment”
2017-07-26
MediMabBio Chosen for Up to $1 Million Funding from the TIPS Program
«
1
2